GNMLF: AI 评分 52/100 — AI 分析 (4月 2026)

Genomma Lab Internacional is a Mexican pharmaceutical company focused on developing, marketing, and selling over-the-counter (OTC) drugs and personal care products. The company operates both in Mexico and internationally, offering a diverse portfolio of branded products.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Genomma Lab Internacional is a Mexico-based pharmaceutical company specializing in the development, marketing, and sale of over-the-counter (OTC) drugs and personal care products across Mexico and international markets. With a diverse portfolio of branded products and a focus on consumer healthcare, Genomma Lab maintains a strong presence in the generic drug market.

GNMLF是做什么的？

Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is headquartered in Mexico City. The company has grown to become a significant player in the over-the-counter (OTC) pharmaceutical and personal care product market, both in Mexico and internationally. Genomma Lab develops, markets, and sells a wide range of branded products across various categories, including skin care, health and wellness, hair care, pain relief, cough and cold remedies, gastrointestinal solutions, sexual health products, antiperspirant deodorants, hand sanitizers, isotonic drinks, and razors. The company's product portfolio includes well-known brands such as Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, and Vanart. These brands cater to a diverse consumer base, addressing various health and personal care needs. Genomma Lab also offers pharmaceutical products, including analgesics, antifungals, and hemorrhoid treatments, under brands like Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, and XL-3. The company continues to innovate and expand its product offerings to meet evolving consumer demands and market trends. With a strong distribution network and marketing capabilities, Genomma Lab maintains a competitive position in the consumer healthcare industry.

GNMLF的投资论点是什么？

Genomma Lab Internacional presents a compelling investment case based on its established market position in the OTC pharmaceutical and personal care sector. The company's diverse product portfolio and strong brand recognition drive consistent revenue generation. With a P/E ratio of 10.64 and a dividend yield of 4.45%, GNMLF offers value and income potential. Growth catalysts include expanding into new geographic markets and product categories. Risks include competition from established pharmaceutical companies and fluctuations in currency exchange rates. The company's beta of 0.45 suggests lower volatility compared to the broader market.

GNMLF在哪个行业运营？

Genomma Lab operates within the competitive drug manufacturers industry, specifically focusing on specialty and generic drugs. The global OTC market is characterized by increasing consumer awareness and self-medication trends. Key competitors include both multinational pharmaceutical giants and regional players. Genomma Lab differentiates itself through its strong brand portfolio and focus on the Latin American market. The industry is subject to regulatory oversight and pricing pressures, impacting profitability.

Drug Manufacturers - Specialty & Generic

Healthcare

GNMLF有哪些增长机遇？

Expansion into new geographic markets represents a significant growth opportunity for Genomma Lab. By leveraging its existing product portfolio and marketing expertise, the company can target underserved markets in Latin America and beyond. This expansion could increase revenue by an estimated 15-20% over the next three years.
Development and launch of new products in high-growth categories such as skincare and wellness can drive revenue growth. Investing in research and development to create innovative products that meet evolving consumer needs will enhance the company's competitive advantage. The global skincare market is projected to reach $180 billion by 2027.
Strategic acquisitions of complementary businesses or brands can accelerate growth and expand Genomma Lab's market presence. Identifying and acquiring companies with strong market positions in adjacent categories or geographies can provide synergies and increase market share. This strategy could contribute to a 10-15% increase in revenue over the next five years.
Enhancing the company's e-commerce capabilities and online presence can drive sales and reach a wider customer base. Investing in digital marketing and online sales channels will allow Genomma Lab to capitalize on the growing trend of online shopping. E-commerce sales are projected to account for 20% of total retail sales by 2028.
Increasing focus on sustainable and eco-friendly products can attract environmentally conscious consumers and enhance the company's brand image. Developing and marketing products with sustainable packaging and ingredients will appeal to a growing segment of the market. The market for sustainable products is projected to grow at a rate of 8-10% per year.

Market capitalization of $0.97 billion indicates a mid-sized player in the pharmaceutical market.
P/E ratio of 10.64 suggests the company is potentially undervalued compared to its earnings.
Profit margin of 9.3% demonstrates the company's ability to generate profit from its sales.
Gross margin of 62.6% indicates efficient cost management in product manufacturing and sales.
Dividend yield of 4.45% provides an attractive income stream for investors.

GNMLF提供哪些产品和服务？

Develops over-the-counter (OTC) pharmaceutical products.
Markets OTC pharmaceutical and personal care products.
Sells OTC pharmaceutical and personal care products.
Offers skin care products under brands like Cicatricure and Asepxia.
Provides health and wellness products.
Manufactures and distributes hair care products under brands like Tío Nacho and Vanart.
Offers pain relief and cough/cold remedies.
Provides gastrointestinal and sexual health products.

GNMLF如何赚钱？

Develops and acquires brands in the OTC pharmaceutical and personal care space.
Manufactures or outsources the production of its products.
Distributes products through a network of retailers, pharmacies, and online channels.
Markets its products through advertising, promotions, and public relations.
Generates revenue from the sale of its branded products.

Consumers seeking over-the-counter medications and personal care products.
Retailers and pharmacies that stock and sell Genomma Lab's products.
Hospitals and clinics that use Genomma Lab's pharmaceutical products.
Online shoppers purchasing products through e-commerce channels.

Strong brand recognition for key products like Cicatricure and Asepxia.
Extensive distribution network across Mexico and Latin America.
Diverse product portfolio across multiple healthcare and personal care categories.
Established relationships with retailers and pharmacies.
Focus on innovation and new product development.

什么因素可能推动GNMLF股价上涨？

Upcoming: Potential expansion into new Latin American markets by Q4 2026.
Ongoing: Continued growth in the skincare and personal care segments.
Ongoing: Strategic partnerships with major retailers to expand distribution.
Upcoming: Launch of new product lines in the wellness category by Q2 2027.
Ongoing: Increasing brand awareness through targeted marketing campaigns.

GNMLF的主要风险是什么？

Potential: Increased competition from established pharmaceutical companies.
Potential: Fluctuations in currency exchange rates impacting profitability.
Ongoing: Regulatory changes and pricing pressures in key markets.
Potential: Economic downturns affecting consumer spending on OTC products.
Ongoing: Intellectual property infringement and counterfeit products.

GNMLF的核心优势是什么？

Strong brand portfolio in key OTC categories.
Extensive distribution network in Latin America.
Proven track record of product innovation.
Experienced management team.

GNMLF的劣势是什么？

Concentration of revenue in Mexico.
Exposure to currency fluctuations.
Dependence on key brands.
Limited presence in developed markets.

GNMLF有哪些机遇？

Expansion into new geographic markets.
Acquisition of complementary businesses.
Development of new products in high-growth categories.
Increased focus on e-commerce and digital marketing.

GNMLF面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory changes and pricing pressures.
Economic downturns in key markets.
Counterfeit products and intellectual property infringement.

GNMLF的竞争对手是谁？

Biogen Inc. — Focuses on neurological and neurodegenerative diseases. — (BIOGY)
Exchange Traded Concepts Trust — Offers a range of ETFs, including those focused on healthcare. — (EXETF)
Kuspi Corp. — Unknown differentiation due to lack of available information. — (KSPHF)
Luye Life Sciences Group Ltd — Focuses on innovative compounds and drug delivery systems. — (LJUIF)
Novo Nordisk A/S — Specializes in diabetes care and other serious chronic diseases. — (NWKHY)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Juan Marco Sparvieri
Headquarters: Mexico City, MX
Employees: 1,605
Founded: 2012

AI Insight

AI analysis pending for GNMLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Genomma Lab Internacional, S.A.B. de C.V. do?

Genomma Lab Internacional is a pharmaceutical company that develops, markets, and sells over-the-counter (OTC) pharmaceutical and personal care products. The company operates primarily in Mexico and Latin America, offering a diverse portfolio of branded products across various categories, including skin care, health and wellness, hair care, pain relief, and gastrointestinal solutions. Genomma Lab focuses on providing accessible and affordable healthcare solutions to consumers through its extensive distribution network and marketing efforts.

What do analysts say about GNMLF stock?

Analyst coverage of GNMLF is limited due to its OTC listing. However, key valuation metrics such as the P/E ratio of 10.64 suggest potential undervaluation. Growth considerations include the company's expansion into new markets and product categories. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks. There is no strong consensus to recommend buying or selling GNMLF stock.

What are the main risks for GNMLF?

The main risks for Genomma Lab Internacional include competition from established pharmaceutical companies, exposure to currency fluctuations, and regulatory changes in key markets. As an OTC stock, GNMLF also faces risks related to limited financial disclosure and liquidity. Economic downturns in Latin America could negatively impact consumer spending on OTC products. Intellectual property infringement and counterfeit products also pose a threat to the company's brand reputation and revenue.